Answers are grounded in this paper and cite their sources.
CLN-IgG (Pritumuab) was subjected to clinical trials aiming at regression of brain tumors. The mechanism underlying the dramatic recuperation of cancer patient was considered by means of augmentation of idiotypic antibody-mediated internal image transmission of the vimentin epitope-vipidam. Silencing of prionogenicity of vimentin by chaperonic antibody CLN-IgG was a pertinent modality to elongate cancer patient's senescence with little side effect.
No takes yet. Share an insight, caveat, or question.
Hugwil AV (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: